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ABSTRACT

Ochs, Sharon D. M.S., Department of Pharmacology and Toxicology, Wright State
University, 2011. Elucidating transcription factor regulation by TCDD within the hs1,2
enhancer.

Immunoglobulin heavy chain (IgH) expression and Ig secretion is inhibited by the
environmental contaminant 2,3,7,8-tetrachlorodibenzo-ρ-dioxin (TCDD). Within the IgH
gene, the 3’ IgH regulatory region (3’IgH RR) has been identified as a transcriptional
target of TCDD. The 3’IgH RR, which in part regulates transcription of the IgH gene, is
composed of four enhancers in the mouse: hs3a; hs1,2; h3b; hs4 and three enhancers in
the human: hs3a; hs1,2; hs4. In humans the hs1,2 enhancer has an invariant sequence (IS)
containing a DRE, NF-κB, NF1 and AP-1 binding site. Also, the enhancer has an
AP1.ETS and Oct site located 5’ to the IS. The human hs1,2 enhancer is sensitive to
TCDD-induced modulation but in contrast to the mouse hs1,2 and 3’IgH RR, TCDD
activates the human hs1,2 enhancer. The current study demonstrates the complexity of
how TCDD differentially induces modulation between mouse and human and what role
these binding sites may have.
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I. INTRODUCTION

2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD)
Dioxins are composed of a polyhalogenated aromatic hydrocarbon and share
similar biological mechanisms of action.

Based on their hydrophobic properties,

resistance towards metabolism and long half-life, dioxins tend to bioaccumulate and
persist as environmental contaminants (Van den Berg et al., 1998).

2,3,7,8-

tetrachlorodibenzo-p-dioxin, also known as TCDD, is the prototypical dioxin (Fig. 1).
Much research has been dedicated to TCDD, because of its extreme potency as a toxin
and its inadvertent exposure to humans through a number of well-publicized events.

Figure 1. Chemical structure of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD).
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TCDD is not intentionally produced, except on small scale for research purposes.
Rather, it is synthesized from chemical reactions or incomplete combustion processes
involving the presence of chlorine (paper bleaching, metal production, waste incineration,
fossil fuel and wood combustion, volcanic activity) (ATSDR, 1998). In the 1960s and
1970s

TCDD

contaminated

chlorophenoxy

herbicides,

such

as

2,4,5-

trichlorophenoxyacetic acid. This acid was a component of Agent Orange, a defoliant
used during the Vietnam War (Schecter et al., 2006). Additionally, industrial accidents
or environmental application of substances contaminated with TCDD led to evacuations
of areas around Love Canal in Niagara Falls, New York, Times Beach, Missouri, and
Seveso, Italy (Friedman et al., 1999; Reggiano, 1979). More recently, a large number of
pig and poultry farms in Europe were closed after dioxin contamination was discovered
in the animal feed.
TCDD exposure occurs by ingestion, inhalation or dermal contact when it is
incorporated into food, water, dust, smoke or air (Mandal, 2005). Toxic responses to
TCDD are broad and depend upon many factors, like exposure dose, duration of exposure
and type of species.

In vivo studies have correlated TCDD to a multitude of

pathophysiological abnormalities related to brain function, reproduction, hormone
signaling and immunity (Mandal, 2005). Moreover, TCDD has been shown to promote
tumor growth and is classified as a human carcinogen (IARC, 1997). In all mammalian
species tested, lethal doses of TCDD lead to excessive loss in body weight preceding
death (wasting syndrome) (IARC, 1997). Also, short-term exposure to high levels of
TCDD in humans can disturb liver function and cause chloracne, a severe acne-like
condition (Marinkovic et al., 2010). The mechanism involved in much of TCDD’s
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toxicity is yet to be determined, but many of its toxic effects are thought to be mediated
via the aryl hydrocarbon receptor (AhR) signaling pathway.

Aryl Hydrocarbon Receptor Signaling
The aryl hydrocarbon receptor (AhR) is a constitutively expressed transcription
factor belonging to the basic-helix-loop-helix/Per-ARNT-Sim family. In its inactivated
state, the AhR is found in the cytosol coupled with several proteins: two heat-shock
protein 90 molecules, p23, and XAP2. To date, a variety of chemicals, pharmaceuticals,
and dietary constituents have been identified as AhR ligands, which can be categorized as
either man-made or natural in origin (e.g. aromatic hyrdrocarbons, omeprazole,
flavonoids) (Abel and Haarmann-Steeman, 2010). When AhR binds a ligand, such as
TCDD, it undergoes a conformational change and dissociates from the cytosolic proteins.
The AhR then translocates into the nucleus to form a complex with the aryl hydrocarbon
receptor nuclear translocator (ARNT). The TCDD/AhR/ARNT complex binds a dioxin
responsive element (DRE; 5’-TNGCGTG-3’) within the promoter or enhancer regions of
sensitive genes and consequently alters gene expression (Fig. 2). When the AhR ligand is
no longer present, receptor signaling is seemingly terminated by either nuclear export of
the receptor, followed by ubiquitination and proteosomal degradation or negative
feedback-inhibition by the AhR repressor, an inhibitor that binds DREs leading to
transcriptional repression (Abel and Haarmann-Steeman, 2010).
The AhR plays an important role in xenobiotic metabolism and therefore the
upregulation of a number of drug metabolizing enzymes.

Induction of CYP1A1, a

member of the cytochrome P450 superfamily of enzymes, is one of the most well-
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characterized gene responses targeted by AhR activation (Fig.2). CYP1A1 is involved in
the biotransformation of substrates in phase I reactions and is highly induced by TCDD
(Whitlock, 1999). In addition to drug metabolism, many studies have shown that the
AhR possesses a multitude of diverse functions and capabilities. A ligand-activated AhR
is directly involved in cross-talk pathways with androgen and estrogen receptor signaling
by co-regulating transcription (Ohtake et al., 2008). Also, UVB irradiation of human
skin can induce metabolites that activate the AhR (Jux et al., 2010). The AhR can further
crosstalk by physically interacting with NF-κB and SP1 and/or altering Nrf2 signaling as
well (Tian et al., 1999; Kobayashi, 1996; Hayes, 2009).

4

Figure 2. Aryl hydrocarbon receptor signaling pathway. TCDD binds to the AhR and
cytoplasmic proteins dissociate. TCDD/AhR translocate to the nucleus and bind ARNT.
The TCDD/AhR/ARNT complex modulates transcription by binding DREs.
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The Immune System
The immune system is comprised of a variety of cells and mechanisms that work
to clear the body of foreign antigens like bacteria, viruses, fungi, and/or parasites. There
are two arms to immunity: innate and adaptive. Innate immunity provides an immediate,
non-specific response towards pathogens and acts as the first line of defense (Medzhitov
& Janeway, 2000). Physical barriers, mucosal surfaces and gut flora all resist infection.
Additionally, phagocytes (macrophages, dendritic cells and neutrophils) recognize
pathogen-associated molecular patterns and release inflammatory mediators. Adaptive
immunity is subsequently activated by the innate system and eliminates specific antigens
by mounting a strong, highly-specific cellular response (Medzhitov & Janeway, 2000).
Ultimately, immunological memory of an antigen is retained so that a faster, more robust
immune response can be achieved upon future exposure to the same antigen. In adaptive
immunity there is cell-mediated immunity that is dominated by T cells and humoral
immunity that is dominated by B cells. Naïve CD4+ TH cells recognize specific epitopes
bound to major histocompatibility complex (MHC) II molecules found only on the
surface of an antigen-presenting cell (B cells, dendritic cells, macrophages).

When

activated, these cells proliferate and differentiate into effector, memory or regulatory TH
cells and effector TH cells will further differentiate into various subtypes. Alternatively,
CD8+ cytotoxic T cells respond to an epitope presented by MHC class I molecules, which
are present on nearly every cell of the body.

MHC II molecules present antigenic

peptides from pathogens of extracellular origin (e.g. bacteria) whereas MHC I molecules
present fragments from pathogens of intracellular origin (e.g. viruses).
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Both cell-

mediated and humoral immunity are interrelated and typically antigen-activated helper T
cells are needed to effectively activate B cells (Cerutti, 2011).

B Cells
When a B cell is activated it eventually undergoes proliferation and differentiation
into a plasma cell. Antibodies, the soluble form of immunoglobulin (Ig), are then secreted
from the plasma cell to mark pathogens for destruction or elimination in an effort to
reduce infection. There are five main isotypes of Ig (IgM, IgA, IgD, IgG, IgE) and each
consists of two identical heavy chains and two identical smaller, light chains linked
together by disulfide bonds (Fig. 3) (Woof & Burton, 2004). Both the heavy and light
chain is composed of a variable region that forms the antigen binding site as well as a
constant region, which is less diverse in its amino acid sequence (Fig. 3). Ig molecules
are defined based on differences between the constant region of their heavy chains (CH)
and each class has distinct effector functions, because of this difference (Woof & Burton,
2004). IgM, IgD, IgG, IgE, and IgA are encoded by their respective C H: Cµ, Cδ, Cγ, Cε,
Cα (Fig. 4). There are two isotypes for the light chain: lambda and kappa, but no
functional differences have been found between the two. Gene segments that encode the
variable region of the light chain are called variable (V) and joining (J) gene segments.
The heavy chain variable region includes diversity (D) gene segments as an additional set
(Fig. 4).
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variable

variable

constant

light chain

heavy chain

Figure 3. Immunoglobulin (Ig) structure. Secreted Ig (antibody) is composed of a
heavy chain and light chain that binds a specific antigen.
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Diversity of the antigen binding site is increased by the random combination of
the gene segments through a process termed, somatic recombination. During B cell
development gene segments are cut and spliced so that a V and J gene segment is selected
and joined for the light chain variable region and likewise a V, D and J segment for the
heavy chain variable region. Following successful rearrangement of the light chain and
heavy chain, an immature B cell will express surface IgM to ensure that there is no
reaction to self-antigen. The B cells that pass this test become mature B cells and use
alternative mRNA splicing to simultaneously produce membrane-bound IgM and IgD.
Before a B cell differentiates and proliferates in response to an antigen it must be
activated either with or without T-cell help. In T-cell dependent activation a T cell
recognizes an antigen that it is specific for and clonally expands and differentiates into
effector cells. This same antigen delivers the first signal to a B cell when it binds the Bcell receptor (BCR), which is composed of a membrane-bound Ig complexed with Igα
and Igβ chains. The second signal is delivered to the B cell when a helper T-cell
activated by the same antigen recognizes a peptide fragment of the antigen bound to the
major histocompatibility complex (MHC) class II molecule on the B-cell surface. These
two signals together are needed to drive B-cell proliferation and differentiation into
plasma cells. In contrast, certain antigens can activate B cells independent of T-cell help.
One such example is lipopolysaccharide (LPS), an outer membrane component of gramnegative bacteria.

In addition to binding an LPS-specific BCR, LPS binds the

CD14/TLR4/MD2 receptor complex, which produces activating signals for inflammatory
cytokines. Whether or not T cells are involved, antibody production may proceed once
the B cell is activated.
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IgM is the first antibody produced, but isotype switching can take place to
change which Ig class is produced by recombining the rearranged V-region DNA with a
different heavy-chain C gene.

Highly repetitive sequences, called switch regions,

mediate recombination whereby the switch region that flanks the µ gene interacts with
the switch region flanking one of the other C genes (Fig. 4). This interaction allows for
excision of the previous C gene as a circular DNA molecule bringing the V region and
new C gene together.

Essentially, antigen specificity can be preserved while the

functional role of the Ig can be altered. Somatic hypermutation can also take place,
which involves point mutations to the rearranged V-region DNA. Ig with differing
affinities are produced that allow for its receptor to possess an enhanced ability to bind a
specific foreign antigen.
In the end, an activated B cell develops into a plasma cell or a long-lived memory
B cell. The Ig secreted from a plasma cell helps clear the pathogen from the body
through various ways. Antibodies can directly bind and neutralize a pathogen or toxin so
that it cannot interact with human cells. Also, antibodies can coat pathogens, referred to
as opsonization, to improve the effectiveness of ingestion by phagocytes. Alternatively, a
memory B cell will persist long-term and retain the surface Ig specific for the foreign
antigen. When exposed to the same antigen in the future, a quicker immune response can
be achieved from the memory B cell, because the time required to get a high affinity,
class switch Ab is reduced.
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TCDD-induced Immunotoxicity
The immune system is an early and sensitive target to TCDD-induced toxicity.
Rodents display a variety of innate and acquired immune-related disturbances following
acute and chronic exposure to low levels of TCDD (Holsapple et al., 1991; Vos, 1997).
Examples of responses to TCDD in rodents include immune-cell dysfunction, thymic
atrophy, susceptibility to infectious diseases and prevention of transplant rejection
(Luster, 1987; Kerkvliet, 2002). Although the exact molecular mechanisms responsible
for the immunosuppressive effects of TCDD have not been clearly established, it is
believed the AhR plays a vital role. One study, for example, showed AhR-deficient mice
were able to mount normal immune responses when exposed to TCDD and challenged
with different antigens (allogeneic P815 tumor cells, sheep red blood cells)
(Vorderstrasse et al., 2001). It seems absence of the AhR does not affect immune system
function, but the receptor is somehow necessary for immune-related effects of TCDD.

TCDD-induced B Cell Dysregulation
TCDD affects B cell maturation, activation, differentiation and to a lesser extent
proliferation (Sulentic and Kaminski, 2011). Cell separation/reconstitution studies of
splenocytes determined that B cells are a direct, cellular target of TCDD-induced
antibody suppression (Holsapple et al., 1986; Dooley and Holsapple, 1988). TCDDcultured B cells activated by lipopolysaccharide (LPS) (T-independent), dinitrophenyl (Tindependent) or sheep red blood cells (T-dependent) provided evidence that inhibition of
antibody production can occur without T-helper function (Holsapple et al., 1986; Dooley
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and Holsapple, 1988). Mitogenic activation increases AhR expression and therefore may
increase a B cell’s responsiveness to TCDD (Allan and Sherr, 2010). When activated by
LPS, mouse B cells (CH12.LX) and purified splenic B cells induce AhR expression
(Marcus, 1998; Sulentic, 1998). In LPS-stimulated CH12.LX cells IgM secretion is
decreased when treated with TCDD while AhR-deficient mouse B cells (BCL-1) did not
demonstrate an inhibition of IgM secretion when activated by LPS (Sulentic, 1998). This
result indicates that antibody production is potentially inhibited by TCDD through an
AhR-dependent pathway (Sulentic, 1998). AhR-/- mice mount normal immune responses
when treated with sheep red blood cells or allogeneic tumor cells and when treated with
TCDD these responses are not suppressed (Vorderstrasse et al., 2001). This demonstrates
that the AhR is not required for normal immune function, but is necessary for TCDDinduced immune suppression (Vorderstrasse et al., 2001).

The Immunoglobulin Heavy Chain Gene Locus
The immunoglobulin heavy chain (IgH) gene locus is comprised of the variable
heavy chain promoter (VH), VDJ region, Eµ intronic enhancer, heavy chain constant
regions (CH) with germline promoters and the 3’ immunoglobulin heavy chain regulatory
region (3’IgH RR) (Fig. 4). There is one 3’IgH RR present in mouse while there are two
3’IgH RRs present in human-likely the result of an evolutionary duplication event (Mills
et al., 1997) (Fig. 4). 3’ to the α1 and α2 heavy chain constant regions are the α1 3’IgH
RR and α2 3’IgH RR, respectively. The 3’IgH RR plays an important role in modulating
transcription of the IgH gene, class switch recombination and somatic hypermutation
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(Cogne et al., 1994; Dunnick et al., 2005; Dunnick et al., 2009). Splenocytes from 3’ IgH
RR-deficient mice show a decrease in µ IgH transcripts, defective class switch
recombination and Ig secretion (Vincent-Fabert et al., 2010).

TCDD

along

with

other AhR ligands of dietary, pharmaceutical, environmental and industrial origin inhibit
transcriptional activity of the 3’IgH RR in LPS-stimulated CH12.LX cells (Sulentic et al.,
2004a; Henseler, 2009). Additionally, several lymphomas have been correlated with
chromosomal translocations between the 3’IgH RR and oncogenes.

In Burkitt’s

lymphoma, translocation of the 3’IgH RR with the cellular oncogene MYC induces
deregulated gene expression (Yan et al., 2007). Furthermore, most follicular lymphomas
contain a chromosomal translocation between the bcl-2 gene and 3’IgH RR that also
deregulates gene expression and increases resistance to cell death (Heckman et al., 2003).
There are four enhancers in the mouse 3’IgH RR (hs3a; hs1,2; hs3b; hs4) and
three enhancers in the human 3’IgH RR (hs3a; hs1,2; hs4) that display DNase I
hypersensitivity (Madisen and Groudine, 1994; Chauveau and Cogne, 1996; Mills et al.,
1997) (Fig. 4). Enhancers of the murine 3’IgH RR display strong synergistic activity
when in combination versus being independent of one another and individual enhancers
show different profiles in transcriptional activity depending on the B cell stage (Madisen
and Groudine, 1994; Saleque et al., 1997; Chauveau, 1998). The hs4 is active throughout
B cell development, the hs1,2 is most active in mature B cells and plasma cells and the
hs3 enhancers have slight activity in activated B cells (Madisen and Groudine, 1994;
Saleque et al., 1997; Chauveau, 1998). As a whole, the 3’IgH RR shows less activity in
pre-B cells compared to surface Ig+ B cells and plasma cells (Ong et al., 1998).
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Figure 4. Immunoglobulin heavy chain (IgH) gene locus. VH, variable heavy chain
promoter; Eμ, intronic or μ enhancer; open rectangles, switch regions upstream of heavy
chain constant chain regions.
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Past research shows that mouse 3’IgH RR transcriptional activity in LPSstimulated CH12.LX cells is inhibited by TCDD (Sulentic et al., 2004a). This effect
parallels TCDD-induced inhibition of µ gene expression and IgM production (Sulentic et
al., 2000). The hs4 and hs1,2 enhancers each contain a DRE-like site that demonstrates
TCDD-inducible binding of AhR/ARNT by EMSA-Western analysis (Sulentic et al.,
2000). Altered binding to these enhancers supports at least a partial role of DREdependent regulation; however, the AhR is known to interact directly and indirectly with
a number of different transcription factors such as, AP-1, NF-κB, and SP1 (Suh et al.,
2002; Tian et al., 1999; Kobayashi et al., 1996). Even though a link between the AhR
and Oct remains unclear, a high frequency of Oct sites were found in AhR-responsive
genes using a genetic algorithm thus suggesting a potential role for the transcription
factor in mediating a response to TCDD (Kel et al., 2004). Additionally, Oct coordinates
with NF-κB as a repressor of mouse hs1,2 activity in plasma cells and like NF-κB could
therefore be modulated by TCDD or the AhR (Michaelson et al, 1996).
To determine which enhancer(s) may be responsible for mediating TCDDinduced inhibition of 3’IgH RR activity, each enhancer was evaluated in isolation.
Transient transfections of LPS-stimulated CH12.LX cells with a reporter plasmid
containing the hs4 enhancer resulted in increased activity by TCDD (Sulentic et al.,
2004b). EMSA analysis indicated AhR/ARNT binding to a region of the hs4 enhancer
containing a DRE and overalapping NF-κB motif, which could explain how TCDD is
mediating the enhancer’s activity (Sulentic et al., 2004b). This outcome is opposite in
comparison to TCDD’s effects on the overall mouse 3’IgH RR so the hs4 enhancer may
have a distinct or unrelated function. Since the mouse hs4 enhancer has the most activity
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of the four enhancers in pre-B cells, it may have greater influence on early B-cell
development and VDJ recombination (Chauveau et al, 1998). One study indicates that
deletion of the hs4 enhancer does not affect in vitro class switch recombination or Ig
secretion in response to cytokine or LPS stimulation (Vincent-Fabert et al., 2009). When
the mouse hs1,2 enhancer was evaluated in CH12.LX cells similarly to the hs4 enhancer,
TCDD inhibited transcriptional activity of the enhancer (Fernando et al., 2012). The
effects on the hs1,2 enhancer mirrors the suppression of LPS-induced 3’IgH RR activity
by TCDD making it possible that the hs1,2 enhancer plays an important role in mediating
transcriptional inhibition of the 3’IgH RR.

The hs1,2 Enhancer
While much effort has focused on studying TCDD-induced responses of the
mouse 3’IgH RR and its enhancers, recent efforts have turned towards human. Unlike
the mouse hs1,2 enhancer, the human hs1,2 enhancer is activated by TCDD in LPSstimulated CH12.LX cells (Fernando et al., 2012).

Activation of the human hs1,2

enhancer is similarly demonstrated in a human B-cell line (IM-9) (Fernando et al., 2012).
The explanation to this interesting dichotomy may be found in the DNA sequences.
While the core region of the mouse and human hs1,2 enhancers is about 90% similar,
there are some notable differences (Mills et al., 1997). The mouse hs1,2 enhancer
contains two binding sites for Pax5: one low-affinity and one high-affinity (Singh and
Birshtein, 1993) (Fig. 5). Pax5, also known as B cell-specific activator protein (BSAP),
is an important transcriptional regulator involved in determining B cell lineage identity
and function. The Pax 5 transcription factor is critical for progenitors to commit to the B-
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cell pathway in early stages while its eventual downregulation permits terminal plasma
cell differentiation (Cobaleda et al., 2007). In LPS-stimulated CH12.LX cells Pax5 levels
decrease, but this down-regulation is inhibited by the presence of TCDD co-treatment
(Yoo et al., 2004; Schneider et al., 2008).

Deregulation of Pax5 and three of its

downstream targets (IgH, Igκ, IgJ) imply a role for the transcription factor in TCDDmediated impairment of B cell differentiation and Ig expression (Schneider et al., 2009).
The human α1 hs1,2 enhancer has a polymorphic region that is absent in the
mouse hs1,2 enhancer. The polymorphism consists of an invariant sequence (IS) of
approximately 55 bp, which can exist one (α1A), two (α1B), three (α1C) or four (α1D) times
and may alter transcriptional activity (Denizot et al., 2001) (Fig. 5). Within the IS are
several binding sites for transcription factors (AP-1, NF1, NF-κB) and also a DRE coremotif analogous to the functional DRE found in the mouse hs1,2 enhancer (Chen and
Birshtein, 1997; Denizot et al., 2001; Giambra et al., 2005; Fernando et al., 2012) (Fig.
5). This polymorphic region has drawn particular interest, because of its association with
a number of diseases involving Ig secretion: celiac disease, IgA nephropathy, and
cutaneous immune-related disorders (Aupetit et al., 2000; Frezza et al., 2004; Cianci et
al., 2008). Of the four alleles α1B correlates with increased prevalence or severity of
these diseases (Aupetit et al., 2000; Frezza et al., 2004; Cianci et al., 2008). However,
there were few observed genomes containing the α1C and α1D so their importance should
not be dismissed (Aupetit et al., 2000; Frezza et al., 2004; Cianci et al., 2008).

It is

possible that increased transcriptional strength from redundant binding sites affects
outcomes to correlated diseases. Furthermore, frequency of the α1A, α1B or α1C alleles is
distributed differently among various population groups indicating the polymorphism
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may be considered a reliable anthropogenetic marker (Giambra et al., 2006). African
populations have the highest frequency of the α1C allele while Asian and European
populations have a higher frequency of the α1B allele (Giambra et al., 2006).
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Mouse hs1,2
DRE

NF-κB

GCGTG

CCCCTAAGGG

AP-1/Ets

Oct

TTACTCATTCT

13 bp

ATGCAAAT

113 bp

25 bp
131 bp

NF-κB
GGGGACTCCC

Pax5

GGGACTGGGGGTCCATGACCCCTATTGATGATG
14 bp
8 bp

NF-αP
TTCCGTGTTTCC

Pax5

GGGCAAGGATGGGTGGCTCAACACCCCAGGG

52 bp

Human polymorphic hs1,2
AP-1/Ets

Oct

TGACTCATTCT

ATGCAAAT
24 bp
73 bp

Sp1

DRE

CCCGCCCCCT

GCGTG
6 bp

AP-1

NF1

NF-κB

7 bp

Sp1

GGGACACCCGCCCCCT

TGGCTCAGGCCTCCA
6 bp
55 bp sequence

Figure 5. DNA sequences for the mouse and human hs1,2 enhancer (α1A).
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Significance and Objective
Previous studies showed inhibition of the mouse hs1,2 enhancer by TCDD
whereas the human hs1,2 enhancer is activated (Fernando et al., 2012). It is reasonable
that these diverging results may be due to differences in the DNA sequence. As such, it
is hypothesized that specific transcription factor binding sites of the mouse hs1,2
enhancer and the human polymorphic hs1,2 enhancer differentially modulate TCDDinduced activity. Objective one was to evaluate the transcriptional activity of the Pax5
binding site that is present in the mouse hs1,2 enhancer yet absent in the human. Having
two Pax5 binding sites in the mouse hs1,2 enhancer and none in the human hs1,2
enhancer may explain why TCDD inhibits the enhancer’s activity in the mouse yet
activates it in the human. Objective two was to determine what role the AhR plays in
TCDD-inducibility of human hs1,2 enhancer activity.

Since the human hs1,2 enhancer

contains binding sites that are directly or indirectly effected by TCDD or the AhR, it is
important to establish what involvement the AhR has in enhancer modulation. Objective
three was to evaluate the role of specific transcription factors in the human polymorphic
hs1,2 enhancer. The IS is especially interesting, because it is associated with several
immune-related diseases (e.g. celiac disease, IgA nephropathy, and cutaneous immunerelated disorders) and contains transcription factor binding motifs that have been shown
to interact with the AhR or be modulated by TCDD.
The current study has significant implications for several reasons. First of all, it
exemplifies the complexity of translating mouse studies to human risk assessment,
because there are sequence differences in the DNA. Some transcription factor binding
sites are contained within both the mouse and human hs1,2 enhancer (AP-1/Ets, Oct,
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DRE, NF-κB) while other binding motifs are only in the mouse (NF-αP, Pax5) or the
human (Sp1, NF1, AP-1) (Fig. 5). Also, this study will further elucidate the mechanism
involved in TCDD-induced modulation of the hs1,2 enhancer. Evaluating the
transcriptional activity of specific binding motifs will help clarify the pathway. Finally,
researching the 3’IgH RR and hs1,2 enhancer is important, because they are sensitive to
chemical-induced modulation and associated with a number of lymphomas and Igsecreting diseases. Understanding how this region is governed could provide insight to
the etiology of certain disease states and how they could be altered along with how these
diseases could be environmentally triggered.
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II. MATERIALS AND METHODS

Chemicals and Reagents
TCDD purchased from AccuStandard, Inc. (New Haven, CT) comes dissolved in 100%
DMSO and the certificate of analysis reports 99.1% purity. The AhR antagonist 2methyl-2H-pyrazole-3-carboxylic

acid-(2-methyl-4-o-tolyl-azo-phenyl)-amide

(CH-

223191), previously characterized by Kim et al., (2006) was purchased from Calbiochem
(Carlsbad, CA) and dissolved in 100% DMSO. LPS from Escherichia coli and DMSO
were purchased from Sigma Alrich (St. Louis, MO). The LPS was dissolved in 1x
sterile-filtered PBS.

Cell Line Model
The CH12.LX mouse B cell line, compliments of Dr. Geoffrey Haughton (University of
North Carolina, Chapel Hill, NC), is derived from the murine CH12 B-cell lymphoma
arising in a B10.H-2aH-4bp/Wts (2a4b) mouse. The CH12.LX cell was characterized by
Bishop and Haughton (1986) and has been used extensively in immunological and
toxicological research. There is high AhR expression and a functional AhR signaling
pathway as well as inhibition of LPS-induced Ig expression by TCDD (Sulentic et al.,
1998, 2000). For these reasons using the CH12.LX cell line for dioxin studies is useful
and will help initiate further studies in human cell lines.
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Cell Culture Conditions
Cells were kept at 37°C in a 5% CO2 atmosphere and grown in complete media.
The complete media consisted of RPMI-1640 (Mediatech, Herndon, VA) enhanced with
2 mM L-glutamine, 10% bovine calf serum (Hyclone, Logan, UT), 13.5 mM HEPES, 0.1
mM nonessential amino acids, 1.0 mM sodium pyruvate, 100 units/ml penicillin, 100
µg/ml streptomycin, 50 µM β-mercaptoethanol and 23.8 mM sodium bicarbonate.

Reporter Plasmid Constructs
The human polymorphic plasmids utilize the pGL3 basic luciferase reporter
construct (Promega, Madison, WI) containing ampicillin resistance and the luciferase
gene. The enhancerless variable heavy chain promoter (V H) plasmid and the α1A, α1B and
α1C plasmids were a generous gift from Dr. Michel Cogné (Université de Limoges,
France) (Fig. 6). Of the plasmids that contain the human hs1,2 enhancer there is an
invariant sequence (IS) that may be present one (α1A), two (α1B) or three (α1C) times (Fig.
6). The IS can also be present four (α1D) times, but was not studied because of low
prevalence. Each IS is approximately 55 bp in length and contains several transcription
factor binding sites (AP-1, NF1, NF-κB, DRE), as previously mentioned (Chen and
Birshtein, 1997; Denizot et al., 2001; Giambra et al., 2005; Fernando et al., 2012). The
DRE and AP-1 binding sites found in the third IS of the α1C are not conserved. However,
isolation of genomic DNA from human buccal cells indicated conservation of both these
sites.

23

VH

~5 kb

Luciferase

VH

α1A
~5.5 kb

Luciferase
VH

α1B
~5.6 kb

~5.6 kb

α1 hs1,2

Luciferase
VH

α1C

*
**
α1 hs1,2

Luciferase
VH

***
α1 hs1,2
* = polymorphic repeat

Figure 6. Human polymorphic hs1,2 reporter plasmid constructs. The asterick (*)
represents the IS that may be present one (α1A), two (α1B) or three (α1C) times.
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Site-directed Mutagenesis
The QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA) consists of a four-step process involving plasmid preparation, temperature cycling,
digestion, and finally transformation. Each mutation reaction used 5 µl of 10X reaction
buffer, 100 ng of parental template, 125 ng each of forward and reverse mutation primers,
1 µl of dNTP mix, 1.5 µl of QuikSolution reagent and ddH20 for a final volume of 50 µl.
1 µl of QuikChange Lightning Enyzme was added before thermal cycling.

PCR

conditions used are as follows: 95ºC for 2 min followed by 18 cycles at 95ºC for 20 s,
60ºC for 10 s, 68ºC for 2.75 min (30 sec/kb of plasmid length), then 68ºC for 5 min.
After the PCR reaction, the parental plasmid was digested by incubating the PCR product
with Dpn I (2 μL/50 μL reaction) for 5 min at 37ºC. 2 µl of Dpn I-treated DNA was used
to transform 45 µl of XL10-Gold® ultracompetent cells. Plasmid DNA was isolated
from transformed colonies and sequenced to ensure quality and accuracy of the mutations
(Retrogen, Inc., San Diego, CA). For the α1A plasmid one high-affinity Pax5 site was
added and the AP-1, NFκB, DRE, Oct, AP1.ETS, 5’ SP1 and 3’ SP1 sites were mutated:
termed α1A+Pax5, α1AAP1mut, α1ANFκBmut, α1ADREmut, α1AOctmut, α1AAP1.ETSmut,
α1ASP1.1mut and α1ASP1.2mut, respectively (Table 1).

Additionally, the invariant

sequence (IS) was deleted from the α1A (α1AISdel) and mutants containing the IS deleted
plus the Oct site mutated (α1AISdelOctmut) and the DRE site plus NF-κB mutated
(α1ADRE.NFκBmut) were also generated (Table 1). In the α1B plasmid the first IS was
deleted (α1BIS1del) or the AP-1 (α1BAP1.1mut), NF-κB (α1BNFκB.1mut), DRE
(α1BDRE.1mut) sites were individually mutated from the first IS (Table 2). Lastly, for
the α1C plasmid the third IS was deleted (α1CIS3del) and the NF-κB site in the first IS was
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mutated (α1CNFκB.1mut) (Table 2). A sequenced human sample containing the α1C
hs1,2 enhancer showed consensus-matching DRE and AP-1 sites in the third IS so both
sites were mutated and restored back to their respective consensus sequences
(α1CClinical) (Table 2). Mutations of transcription factor binding sites were determined
based off of enzyme mobility shift assay data and TFSEARCH, an online transcription
factor profile database (Grant et al., 1995; Heinemeyer et al., 1998; Yao and Denison,
1992; Lenardo et al., 1987)
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α1A+Pax5

F: 5’- GTGGTCCCAGTGTCAGCCCTGGGGTGTTGAGCCACCCATCCTTGC CCTAACCCAAGTGGGCCT -3’
R: 5’- AGGCCCACTTGGGTTAGGGCAAGGATGGGTGGCTGCACACCCCA GGGCTGACACTGGGACCAC -3’

α1AAP1mut

F: 5'-TGTCCCCGAATCTGGAGGCCCTTAGATGCCTGGCCACGCTGGGGGAG-3
CCGGACTCGGTCGG
GGCCTGAGCCAGCC
R: 3'-ACAGGGGCTTAGACCTCCGGGAATCTACGGACCGGTGCGACCCCCTC-5'

α1ANFκBmut

F: 5'-CCTGTCCTGGGGGAGGGGGCAGTTCTTCTACAATCTGGAGGCCTGAGCCAG-3'
CGCCCACAGGGGCTTA
GCGGGTGTCCCCG AAT
R: 3'-GGACAGGACCCCCTCCCCCGTCAAGAAGATGTTAGACCTCCGGACTCGGTC-5'

α1ADREmut

F: 5'-CCTGAGCCAGCCTGGCAGACTTGGGGGAGGGGGCGGG-3'
ACCGGTGCGACCC
TGGCCACGCTGGG
R: 3'-GGACTCGGTCGGACCGTCTGAACCCCCTCCCCCGCCC-5'

α1AOctmut

F: 5'-CATGTTTTCGGTGTGGAACAAACAACCGACTTAGGGTGCCCTGAGGGCCAAGTCTGCCCAGA-3'
TGGT AAACGT ACACG
ACCATT T GCAT G TGC
R: 3'-GTACAAAAGCCACACCTTGTTTGTTGGCTGAATCCCACGGGACTCCCGGTTCAGACGGGTCT-5'

α1AISdel

F:5’-GGGGGAGGGGGC……………….GGGAGAATCGTG -3’
CCCCGCCC……..CGACCCT
GGGCGGG..........GCTGGGA
R: 3’-CCCCCTCCCCCG……………..….CCCTCTTAGCAC-5’

α1AAP1.ETSmut

F: 5'-GTGCCCTGAGGGCCAAGTCTGCCCCTAGTTGGCCCCTCAAGGAGAAACAGATCAGAGCC-3'
GG TCT T ACTCAG TGA
CCAG AATGAGT C ACT
R: 3'-CACGGGACTCCCGGTTCAGACGGGGATCAACCGGGGAGTTCCTCTTTGTCTAGTCTCGG-5'

α1ASP1.1mut

F: 5'-GGGCCTGTCCTGGGGGAGGATCGACTTGTCCCCGAATCTGGAGGC-3'
CTCCCCCGCCCAC
GAGGGGGCGGGTG
R: 3'-CCCGGACAGGACCCCCTCCTAGCTGAACAGGGGCTTAGACCTCCG-5'

α1ASP1.2mut

F: 5'-CAGCCTGGCCACGCTGGGGGAGGATCGACTAGAATCGTGCAAGCTATTTCTGG-3'
CTCCCCCGCCCT
GAGGGGGCGGGA
R: 3'-GTCGGACCGGTGCGACCCCCTCCTAGCTGATCTTAGCACGTTCGATAAAGACC-5'

α1ADRE.NFkBmut

Serial mutagenesis performed using primer sets from α1ADREmut and α1ANFκBmut

α1AISdelOctmut

Serial mutagenesis performed using primer sets from α1AISdel and α1AOctmut

Table 1. α1A site-directed mutagenesis primers. Bolded sequence denotes addition or
mutation. Underlined sequence denotes original sequence before mutation or deletion.
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α1BAP1.1mut

F: 5'-CTCCCCCAGCGTGGCCAGGCATCTAAGGGCCTCCAGATTCGGGGACA-3'
CGACCGAGTC
GCTGGCTCAG
R: 3'-GAGGGGGTCGCACCGGTCCGTAGATTCCCGGAGGTCTAAGCCCCTGT-5'

α1BNFκB.1mut

F: 5'-GGCTCAGGCCTCCAGATTCGGATCTTAGCCCCCACCACAGCGTGGCCAG-3'
GCCCCTGTGGGG
CGGGGACACCCC
R: 3'-CCGAGTCCGGAGGTCTAAGCCTAGAATCGGGGGTGGTGTCGCACCGGTC-5'

α 1BDRE.1mut

F: 5'-TCTCCCGCCCCCTCCCCCAAGACTGCCAGGCTGGCTC-3'
GTCGCACCG
CAGCGTGGC
R: 3'-AGAGGGCGGGGGAGGGGGTTCTGACGGTCCGACCGAG-5'

α 1BIS1del

F: 5'- GCACGATTCTCCC……………..………….CCCCACCACAGCG -3'
GGGCGGG…………..GGGGGGGT
CCCGCCC…………....CCCCCCCA
R: 3'-CGTGCTAAGAGGG…………………....…..GGGGTGGTGTCGC-5'

α1CNFκB.1mut

F: 5'-GTCCTGGGGGAGGGGGCAGTTCTTCTCGAATCTGGAGGCCTGA-3'
GCCCACAGGGGC
CGGGTGTCCC CG
R: 3'-CAGGACCCCCTCCCCCGTCAAGAAGAGCTTAGACCTCCGGACT-5'

α1cClinical

F: 5’-CTGGAGGCCTGAGCCAGCCTGGCCACGCTGGGTGGGTGGCGGCTGCAGCT-3’
GGTGGGCCAC………. GCACACA
CCACCCGGT G………..CGTGTGT
R: 3’-GACCTCCGGACTCGGTCGGACCGGTGCGACCCACCCACCGCCGACGTCGA-5’

α1cIS3del

F: 5'-CGCTGTGGTGGGG……………GCTGCAGCTGCAG-3'
CCCGGG…GCGCGA
GGGCCC…CGCGCT
R: 3'-GCGACACCACCCC……………CGACGTCGACGTC-5'

-

Table 2. α1B and α1C site-directed mutagenesis primers. Bolded sequence denotes
addition or mutation. Underlined sequence denotes original sequence before mutation or
deletion.
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Transient Transfection
1.0 x 107 cells were pelleted by centrifugation at 300 x g for 5 minutes at 4°C.
Media was removed and cells were resuspended with 10 µg of plasmid and enough media
to bring the final volume up to 200 µl. 200 µL (1.0 x 107 cells) was transferred to a 2mm
electroporation cuvette and electroporated at 250 V, 150 µF, and 75 ohms. Each plasmid
was transfected multiple times and cells were pooled and diluted to obtain 2 x 10 5
cells/mL. Transfected cells were cultured in the absence of any additional treatment
(naïve, NA) or treated with 0.01% DMSO (vehicle control-0 nM TCDD) or TCDD (0.01
nM, 0.1 nM, 1.0 nM, 10 nM) in the absence or presence of LPS (1.0 or 0.1 µg/ml)
stimulation. Different LPS concentrations were used, because different lots of LPS
varied in potency. Cells were aliquoted into 12-well plates (n=3) and incubated at 37°C
in 5% CO2 for 24 hours. In AhR antagonist studies, cells were pre-treated with the
antagonist (15µM) for 1 hour prior to additional treatments.

Luciferase Assay System
After the 24 hour incubation period, cell culture plates were centrifuged at 1800 x
g for 5 minutes at 4°C. Supernatant was removed and cells were lysed with 1x lysis
buffer (Promega, Madison, WI) and immediately frozen at -80°C for no less than 1 hour.
To quantify gene expression the Luciferase Assay System (Promega, Madison, WI) was
used to measure luciferase enzyme activity. Samples were thawed to room temperature
and centrifuged at 20,000 x g for 5 minutes at 4°C. 20 µl of sample lysate was mixed
with 100 µl of luciferase substrate reagent and a single-tube luminometer (Berthold
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Detection Systems, Oak Ridge, TN) reported light measurements as relative light units
(RLUs) following each reaction.

Transfection Efficiency
An additional group of naïve cells were seeded for each transfected plasmid to
determine transfection efficiency. TCDD or LPS treatments do not affect transfection
efficiency (data not shown). DNA was isolated through a genomic DNA miniprep kit
(Sigma Aldrich, St. Louis, MO) at 4 hrs post-transfection and diluted 10-fold. Real-time
polymerase chain reaction (RT-PCR) was performed by using absolute quantification. In
a 96-well plate each sample well contained 23 µl of the reaction master mix [12.5 µl 2x
SYBR Green (Applied Biosystems, Warrington, UK), 1 µl 10 pmol/µl forward primerpGL3 luciferase, 1 µl 10 pmol/µl reverse primer-pGL3 luciferase, and 8.5 µl purified
water] and 2 µl of sample DNA.

The forward and reverse primers are 5’-

ACTGGGACGAAGACGAACACTT-3’ and 5’-TCAGAGACTTCAGGCGGTCAA-3’,
respectively. Sample PCR data was compared to a standard luciferase reporter plasmid
with concentrations ranging from 0.1 ng/µl to 1x10-6 ng/µl. Amount of transfected
plasmid (ng) was calculated by taking the concentration of DNA from the PCR results
(ng/µl) x the volume of DNA added (2µl) x the fold dilution (10). Number of plasmids
per cell was calculated from the equation: [ng of plasmid DNA x number of plasmids/ng]
÷ total number of cells isolated (previously described in Sulentic et al., 2004).
Luciferase activity was normalized to the wildtype plasmid based on plasmids per cell.
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Statistical Analyses of Data
Comparisons between treatment groups (n=3) of the same reporter plasmid were
analyzed using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post test.
Significant differences in luciferase activity (mean ± SEM) were compared to the
corresponding vehicle control and represented by “*”, “**”, “***” at p<0.05, p<0.01 and
p<0.001, respectively. Differences in TCDD-induced fold change was determined in the
same manner and denoted by “‡”, “‡‡”, “‡‡‡” at p<0.05, p<0.01 and p<0.001,
respectively. Differences in luciferase activity or fold change between reporter plasmids
were analyzed using a 2-way ANOVA with Bonferroni post test. Daggers, “†”, “††”,
“†††”, denote significant differences between different reporter plasmids at p<0.05,
p<0.01 and p<0.001, respectively.

Multiple, separate experiments (n=3 for each

treatment group) were used to generate TCDD-induced fold change results (mean ±
SEM). Synergism was calculated by normalizing relative light units (RLUs) of plasmids
to the average NA RLU of the wildtype plasmid (V H or α1A). RLU data has already
undergone normalization to transfection efficiency. The average DMSO vehicle RLU
was subtracted from treatment RLUs of its respective plasmid enable to compare an
additive effect (i.e. “L” + “TCDD”) versus a co-treatment effect (i.e. “LPS + TCDD”).
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III. RESULTS
Insertion of a Pax5 binding site lowers transcriptional activity of the human hs1,2
enhancer
Previous transient transfections of CH12.LX cells show that TCDD inhibits
transcriptional activity of the mouse hs1,2 enhancer yet activates the human hs1,2
enhancer (Fernando et al., 2012). It is possible that these diverging outcomes may be due
to the presence of two Pax5 binding sites (one high-affinity and one low-affinity) in the
mouse hs1,2 enhancer and none in the human hs1,2 enhancer. The B-cell lineage specific
activator protein (BSAP) that binds Pax5 sites is expressed early in B-cell differentiation,
but is consequently down-regulated following B-cell activation (e.g. LPS).

TCDD

treatment inhibits this natural downregulation of BSAP (Yoo et al., 2004; Schneider et
al., 2008).
Using site-directed mutagenesis, one high-affinity Pax5 binding site was added to
the human α1A plasmid (α1A + Pax5). Overall transcriptional activity was lowered by the
Pax5 site and significant differences in luciferase activity were observed between
plasmids for nearly every unstimulated and LPS-stimulated treatment (Fig. 7A). Basal
activity was minimally lowered by insertion of the Pax5 site while LPS-induced activity
was markedly suppressed (Fig. 7A). Furthermore, α1A demonstrated synergism from
LPS/TCDD cotreatment while α1A + Pax5 did not (Fig. 7A). However, contrary to
expectation, the Pax5 binding site did not seem to alter TCDD-induced fold-change
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activation of the human hs1,2 enhancer (Fig. 7B). Even though TCDD still increased α1A
transcriptional activity in a concentration-dependent manner that appeared unrelated to
the Pax5 site overall transcription was still lower for α1A + Pax5 (Fig. 7A and 7B).
Although these outcomes may dismiss the role Pax5 may have in the inhibition of mouse
hs1,2 activity by TCDD further consideration should be warranted, because of the
complexity involved in Pax5 regulation.
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Figure 7. A Pax5 site decreases overall transcriptional activity of the α 1A. CH12.LX
cells were transiently transfected with α1A or α1A + Pax5 reporter plasmids. Transfected
cells were either cultured in the absence of any additional treatment (naïve, NA) or
treated for 24 h with 0.01% DMSO vehicle (0 nM TCDD) or TCDD (0.001-10.0 nM) in
the absence or presence of LPS (1 µg/ml) stimulation. A. Luciferase enzyme activity
(mean ± SEM, n=3) is represented on the y-axis as relative light units normalized to
transfection efficiency. C represents the LPS alone control. B. Fold change is
represented on the y-axis relative to the respective DMSO vehicle control and was
generated from averaging the means of independent experiments (n=3 for each treatment
group within each experiment). Comparisons between treatment groups were analyzed
using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post test.
Asterisks, “*”, “**”, or “***” denote significance compared to the corresponding vehicle
set to 1 at p<0.05, p<0.01 or p<0.001, respectively. Comparisons between reporter
plasmids were analyzed using a 2-way ANOVA Bonferroni post test. Daggers, “†”,
“††”, “†††”, denote significant differences between reporter plasmids for each treatment
at p<0.05, p<0.01 and p<0.001, respectively. Vertical line represents significance
difference between all treatment groups between reporter plasmids at p<0.001. > denotes
synergistic activation by LPS and TCDD cotreatment compared to the activation of either
treatment alone. Results are representative of 5 separate experiments.
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TCDD activates the human polymorphic hs1,2 enhancer in an AhR-dependent
manner
The antagonist, CH-223191, was used to test if the AhR is essential for TCDDinduced activation of the human polymorphic hs1,2 enhancer. CH12.LX cells were
transiently transfected with the VH, α1A, α1B or α1C luciferase reporter plasmids then
treated with the AhR antagonist making the receptor inaccessible and unable to
translocate to the nucleus. Transcriptional activity of basal and LPS levels of the V H
remained low while α1A and α1B had similarly higher activity and α1C demonstrated the
most activity (Fig. 8A). TCDD expectedly activated the human hs1,2 enhancer when
containing one, two or three invariant sequences in both unstimulated and LPS-stimulated
cells (Fig. 8A and 8B ). Cells treated with both the antagonist and TCDD displayed a
reversal of enhancer activation thus exemplifying the necessity of the receptor (Fig. 8A
and 8B). Also, α1A, α1B and α1C demonstrated synergism from LPS/TCDD cotreatment
compared to either treatment by itself (Fig. 8A). The fold change between the human
polymorphic reporter plasmids were quite similar, which means that the number of
invariant sequences present may be less important to what degree the human hs1,2
enhancer is activated by TCDD (Fig. 8B). In essence, these results indicate that the AhR
is necessary for TCDD to activate the enhancer, but whether it is directly or indirectly
involved in the mechanism is yet to be determined. Either the TCDD/AhR/ARNT
complex is binding the hs1,2 enhancer or TCDD and/or the AhR is altering binding of
another transcription factor.
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Figure 8. TCDD-induced activation of the human polymorphic enhancer is AhR
dependent. CH12.LX cells were transiently transfected with VH, α1A, α1B, or α1C reporter
constructs. Transfected cells were either pre-treated for 1 hr with 15 µM AhR antagonist
(CH-223191), 0.15% DMSO, or media alone then cultured for 24 h in the absence or
presence of LPS (1.0 µg/mL) stimulation and either media alone, 0.01% DMSO, or 1 nM
TCDD. “Control” denotes either unstimulated naive or LPS alone. A. Luciferase
enzyme activity (mean ± SEM, n=3) is represented on the y-axis as relative light units
(RLUs) normalized to transfection efficiency. B. Fold change is represented on the yaxis relative to the respective DMSO vehicle control and was generated from averaging
the means of independent experiments (n=3 for each treatment group within each
experiment). Significance was determined by a 1-way ANOVA followed by a Dunnett’s
Multiple Comparison post test: “*”, “**”, “***”, significance compared to the
corresponding DMSO vehicle control at p<0.05, p<0.01 and p<0.001, respectively; “‡”,
“‡‡”, “‡‡‡”, significant difference between TCDD alone and TCDD + AhR antagonist.
Significance compared to the VH reporter was determined by a 2-way ANOVA with a
Bonferroni’s post-hoc test: “†” and “†††”, significance at p<0.05 and p<0.001,
respectively. > denotes synergistic activation by LPS and TCDD cotreatment compared
to the activation of either treatment alone. Results are representative of three separate
experiments.
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Deletion of the invariant sequence lowers overall transcriptional activity of the
human hs1,2 enhancer
As previously mentioned the invariant sequence (IS) contains a number of
transcription factor binding sites (DRE, AP-1, NF1, NF-κB) and is flanked by SP1 sites
on both the 5’ and 3’ end (Chen and Birshtein, 1997; Denizot et al., 2001; Giambra et al.,
2005; Fernando et al., 2012). TCDD and/or the AhR have been shown to affect these
transcription factors so evaluation of this region may explain how TCDD induces the
hs1,2 enhancer.

The α1A and α1B plasmids contain one and two IS, respectively.

Sequencing results of the α1C plasmid indicate the DRE and AP-1 sites of the third IS are
not entirely conserved, but this is contrary to human sequencing (Denizot et al., 2001;
Fernando et al., 2012). To determine how the polymorphism affects transcriptional
activity and TCDD-induced fold change of the hs1,2 enhancer the IS was deleted from
the α1A and α1B. Transient transfection into CH12.LX cells of the deleted IS from the α1A
(α1AISdel) showed a significant decrease in overall transcriptional activity of the human
hs1,2 enhancer (Fig. 9A). Luciferase activity is decreased for both unstimulated and LPS
stimulated treatments when the IS is deleted, but TCDD-induced fold-change activation
is still parallel with α1A (Fig. 9A and 9B). Deleting the first IS from the α1B (α1BIS1del)
revealed a similar outcome to the α1AISdel by lowering the transcriptional activity for all
treatment groups (Fig 9A). Interestingly, the α1BIS1del still displayed more overall
activity than the α1A (Fig 10A). Either the additional IS cannot account for all of the
activity of the enhancer and the other transcription factors found outside the
polymorphism are involved or the deletion generates a compensating mechanism.
Furthermore, the α1A, α1AISdel, α1BIS1del and α1B all showed similar profiles in
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synergistic activation from LPS and TCDD cotreatment (Fig. 9A and 10A). Again, no
significant differences in the magnitude of TCDD-induced fold-change activation were
observed between the α1BIS1del, α1A or α1B, but there is a noticeable decrease in LPS
stimulated fold-changes of the α1BIS1del when compared to the α1B (Fig. 10B). A slight
decrease in α1AISdel stimulated fold-changes is also seen when compared to the α1A,
which may suggest that multiple transcription factors both within and outside the IS work
together to induce activation of the human hs1,2 enhancer by TCDD (Fig. 10B).
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Figure 9. Deletion of the IS from the α1A reduces overall transcriptional activity.
CH12.LX cells were transiently transfected with α 1A or α1AISdel reporter plasmids.
Transfected cells were either cultured in the absence of any additional treatment (naïve,
NA) or treated for 24 h with 0.01% DMSO vehicle (0 nM TCDD) or TCDD (0.001-10.0
nM) in the absence or presence of LPS (1 µg/ml) stimulation. C represents the LPS alone
control. A. Luciferase enzyme activity (mean ± SEM, n=3) is represented on the y-axis
as relative light units (RLUs) normalized to transfection efficiency. B. Fold change is
represented on the y-axis relative to the respective DMSO vehicle control and was
generated from averaging the means of independent experiments (n=3 for each treatment
group within each experiment). Comparisons between treatment groups of the same
plasmid were analyzed using a 1-way ANOVA followed by a Dunnett’s Multiple
Comparison post test. Asterisks, “*” or “**”, denote significance compared to the
corresponding vehicle control at p<0.05 or p<0.01, respectively. Comparisons between
reporter plasmids were analyzed using a 2-way ANOVA Bonferroni post test. Daggers,
“†††”, denote significant differences between reporter plasmids for each treatment at
p<0.001. > denotes synergistic activation by LPS and TCDD cotreatment compared to
the activation of either treatment alone. Results are representative of seven experiments.
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Figure 10. Deletion of the first IS from the α1B lowers overall transcriptional
activity of the human hs1,2 enhancer. CH12.LX cells were transiently transfected with
α1A, α1BIS1del or α1B reporter plasmids. Transfected cells were either cultured in the
absence of any additional treatment (naïve, NA) or treated for 24 h with 0.01% DMSO
vehicle (0 nM TCDD) or TCDD (0.001-10.0 nM) in the absence or presence of LPS (1
µg/ml) stimulation. C represents the LPS alone control. A. Luciferase enzyme activity
(mean ± SEM, n=3) is represented on the y-axis as relative light units (RLUs) normalized
to transfection efficiency. B. Fold change is represented on the y-axis relative to the
respective DMSO vehicle control and was generated from averaging the means of
independent experiments (n=3 for each treatment group within each experiment).
Comparisons between treatment groups of the same plasmid were analyzed using a 1-way
ANOVA followed by a Dunnett’s Multiple Comparison post test. Asterisks, “*” or “**”,
denote significance compared to the corresponding vehicle control at p<0.05 or p<0.01,
respectively. Comparisons between reporter plasmids were analyzed using a 2-way
ANOVA Bonferroni post test. Daggers, “††” or “†††”, denote significant differences
between reporter plasmids for each treatment at p<0.01 or p<0.001. > denotes synergistic
activation by LPS and TCDD cotreatment compared to the activation of either treatment
alone. Results are representative of five experiments.
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Mutation of the invariant sequence AP-1 or NF-κB site increases overall
transcription of the human hs1,2 enhancer
The activator protein-1 (AP-1) binding site (TGGCTCA) and nuclear factor kappa
B (NF-κB) site (GGGACACCC) are located within the invariant sequence (IS) of the
human polymorphic hs1,2 enhancer (Denizot, 2001).

It has been shown that AP-1 or

NF-κB are affected by the AhR or TCDD through cross-talk interactions or altered
binding and expression (Suh et al., 2002; Tian, 2002).

Evaluation of these sites is

therefore necessary, because each may be involved in the TCDD-induced activation of
the human hs1,2 enhancer.
A number of studies have reported TCDD-induced influence on AP-1, but
outcomes vary on whether the transcription factor’s activity increases or decreases. In
LPS-activated CH12.LX cells, one study showed that TCDD upregulated AP-1 binding
within the promoter of B lymphocyte–induced maturation protein-1 (Blimp-1), a critical
regulator of B-cell differentiation and a negative transcriptional repressor of Pax5
(Schneider et al., 2009). In this same study a link was made between TCDD-mediated
suppression of Blimp-1 through AP-1 binding and Pax5 dysregulation (Schneider et al.,
2009). Also, other studies conducted in multiple liver cell types showed an increase in
AP-1 DNA binding activity resulting from genes induced by AhR agonists (Puga et al.,
1992; Ashida et al., 2000). In opposition Suh and coworkers demonstrated that TCDD
inhibited DNA binding and transcriptional activity of AP-1 in LPS-activated CH12.LX
cells (2002). In the same study TCDD was unable to inhibit AP-1 activity in an AhR-
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deficient murine B cell line, BCL-1 (Suh et al., 2002). Even though TCDD-induced
effects on AP-1 differ, it is clear that the transcription factor is targeted.
Site-directed mutagenesis was used to mutate the AP-1 site in the α1A reporter
plasmid (α1AAP1mut), which was then transiently transfected into CH12.LX cells. The
α1AAP1mut resulted in significantly higher transcription of the human hs1,2 enhancer in
both unstimulated and LPS-stimulated CH12.LX cells (Fig. 11A). Also, synergism was
similarly exhibited by α1A and α1AAP1mut. Although differences were not significant,
averaged TCDD-induced fold-change data from several experiments show a trend for
greater activation of α1A as compares to α1AAP1mut at higher concentrations of TCDD in
LPS-stimulated CH12.LX cells (Fig. 11B). The AP-1 site seems to play an important
role in the overall transcription of the human hs1,2 enhancer, but may not play a
dominant role in TCDD-induced modulation.
Like the IS AP-1 site, TCDD-induced modulation of the human polymorphic
hs1,2 enhancer may involve the IS NF-κB site.

NF-κB activity contributes to the

activation of hs1,2 enhancer at the plasma cell stage (Michaelson et al., 1996). Also, the
transcription factor has been found to modulate AhR signaling, which may explain how
TCDD-induced immunotoxicity is mediated (Tian, 2009). Transcriptional activity of the
AhR and NF-κB has been shown to be regulated by the same corepressors and
coactivators, such as Steroid receptor coactivator-1 (SRC-1) and p300/CBP (Tian, 2009).
Because coregulators are required for both pathways, it is possible that competition for
binding occurs causing one pathway to be active while the other pathway is suppressed
(Tian, 2009).
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In its evaluation the NF-κB site was mutated from the α1A reporter plasmid
(α1ANFκBmut). Transient transfections of CH12.LX cells resulted in significantly higher
transcriptional activity from mutation of the NF-κB site in both unstimulated and LPSstimulated cells (Fig. 12A).

Although the overall transcriptional activity differed

between mutated and nonmutated plasmids, TCDD-induced activation and synergism still
occurred in both (Fig. 12A and 12B). In unstimulated cells mutating the NF-κB site did
not affect fold-change activation when compared to α1A (Fig. 12B). However, in LPSstimulated cells the mutation appears to show a lesser degree of fold change activation for
all concentrations of TCDD (Fig. 12B).
Overall transcriptional activity is clearly affected by the AP-1 and NF-κB
mutations. TCDD positively regulates hs1,2 enhancer activity and mutation of these IS
sites further increases TCDD-induced activity. However, mutations of the AP-1 site and
NF-κB site each showed slightly lower TCDD-induced fold changes in LPS-stimulated
CH12.LX cells (Fig. 11B and 12B).

Each site may naturally repress overall hs1,2

activity, but still assist in TCDD-induced enhancer activation. It seems likely that several
transcription factors are coordinating TCDD’s ability to activate the human hs1,2
enhancer.
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Figure 11. Mutation of the IS AP-1 site increases overall transcriptional activity
and slightly decreases TCDD-induced activation of the human polymorphic hs1,2
enhancer. CH12.LX cells were transiently transfected with α1A or α1AAP1mut reporter
plasmids. Transfected cells were either cultured in the absence of any additional
treatment (naïve, NA) or treated for 24 h with 0.01% DMSO vehicle (0 nM TCDD) or
TCDD (0.01-10.0 nM) in the absence or presence of LPS (0.1 µg/ml) stimulation. C
represents the LPS alone control. A. Luciferase enzyme activity (mean ± SEM, n=3) is
represented on the y-axis as relative light units (RLUs) normalized to transfection
efficiency. B. TCDD-induced activation is represented on the y-axis as fold change
relative to the DMSO vehicle. Results (mean ± SEM) were generated from separate
experiments (n=3 for each treatment group within each experiment). Comparisons
between treatment groups of the same plasmid were analyzed using a 1-way ANOVA
followed by a Dunnett’s Multiple Comparison post test. Asterisks, “*”, “**” or “***”,
denote significance compared to the corresponding vehicle control at p<0.05, p<0.01 or
p<0.001, respectively. Comparisons between reporter plasmids were analyzed using a 2way ANOVA Bonferroni post test. Daggers, “††”, “†††”, denote significant differences
between reporter plasmids for each treatment at p<0.01 and p<0.001, respectively. >
denotes synergistic activation by LPS and TCDD cotreatment compared to the activation
of either treatment alone. Results are representative of at least 4 separate experiments.
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Figure 12. Mutation of the IS NFκB site of the α1A increases overall transcription
and slightly lowers stimulated TCDD-induced fold change. CH12.LX cells were
transiently transfected with α1A or NFκBmutα1A reporter plasmids. Transfected cells were
either cultured in the absence of any additional treatment (naïve, NA) or treated for 24 h
with 0.01% DMSO vehicle (0 nM TCDD) or TCDD (0.01-10.0 nM) in the absence or
presence of LPS (0.1 µg/ml) stimulation. C represents the LPS alone control. A.
Luciferase enzyme activity (mean ± SEM, n=3) is represented on the y-axis as relative
light units (RLUs) normalized to transfection efficiency. B. TCDD-induced activation is
represented on the y-axis as fold change relative to the DMSO vehicle. Results (mean ±
SEM) were generated from separate experiments (n=3 for each treatment group within
each experiment). Comparisons between treatment groups of the same plasmid were
analyzed using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post test.
Asterisks, “*”, “**” or “***”, denote significance compared to the corresponding vehicle
control at p<0.05, p<0.01 or p<0.001, respectively. Comparisons between reporter
plasmids were analyzed using a 2-way ANOVA Bonferroni post test. Daggers, “††”,
“†††”, denote significant differences between reporter plasmids for each treatment at
p<0.01 and p<0.001, respectively. > denotes synergistic activation by LPS and TCDD
cotreatment compared to the activation of either treatment alone. Results are
representative of at least 4 separate experiments.
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Mutating the AP1.ETS site decreases overall transcriptional activity of the human
hs1,2 enhancer
The AP1.ETS (TGACTCATTCT) site is located 5’ to the invariant sequence (IS).
There is a single nucleotide difference between the mouse and human AP1.ETS site,
which causes the human AP-1 site to match the consensus (Mills et al., 1997). In the
murine hs1,2 enhancer the AP1.ETS site confers responsiveness to B-cell receptor crosslinking and has a functional role in 3’IgH RR activity (Grant et al., 1995). Following
IgM receptor activation of primary B lymphocytes or BAL-17 cells enhancer activation
was concurrent with recruitment and binding of nuclear factor of activated B cells
(NFAB) to the AP1.ETS site (Grant et al., 1995). Because of its demonstrated role in
murine enhancer activity, it is necessary to explore what role the AP1.ETS site plays in
the human hs1,2 enhancer and how TCDD-induced modulation is altered. Mutation of
the AP1.ETS site (α1AAP1.ETSmut) within the α1A reporter plasmid followed by transient
transfection of CH12.LX cells resulted in a markedly lower overall transcriptional
activity for unstimulated and LPS-stimulated treatments with or without TCDD (Fig.
13A). Additionally, α1A demonstrated more synergism than α1AAP1.ETSmut (Fig. 13A).
Of all the individual transcription factor binding sites evaluated in this study, mutation of
the AP1.ETS was the only one that decreased luciferase activity. Again, no significant
differences in TCDD-induced fold-change were observed between the α1AAP1.ETSmut
and α1A, but the motif seems to account for much activity of the human hs1,2 enhancer
(Fig. 13A & 13B).

46

Luciferase Activity
Normalized for transfection efficiency

A.

6000

Unstimulated

LPS stimulated

>

**

>

α1A
α1AAP1.ETSmut

/
/

*
>

4000

2000

***

***
0

**

†††

†††

†††

TCDD-induced activation
Fold-change relative to DMSO

4

**

>

nM TCDD

B.

>

*

***

**

nM TCDD

LPS stimulated

Unstimulated

/
/

***
**

3

*

***

**

2

α1A
α1AAP1.ETSmut

**
*

***

1
0

.01

.1
1
nM TCDD

10

.01

.1
1
nM TCDD

10

.

Figure 13. Mutation of the AP1.ETS site decreases overall transcriptional activity
of the human hs1,2 enhancer. CH12.LX cells were transiently transfected with α1A or
α1AAP1.ETSmut reporter plasmids. Transfected cells were either cultured in the absence
of any additional treatment (naïve, NA) or treated for 24 h with 0.01% DMSO vehicle (0
nM TCDD) or TCDD (0.01-10.0 nM) in the absence or presence of LPS (0.1 µg/ml)
stimulation. C represents the LPS alone control. A. Luciferase enzyme activity (mean ±
SEM, n=3) is represented on the y-axis as relative light units (RLUs) normalized to
transfection efficiency. B. TCDD-induced activation is represented on the y-axis as fold
change relative to the DMSO vehicle. Results (mean ± SEM) were generated from
separate experiments (n=3 for each treatment group within each experiment).
Comparisons between treatment groups of the same plasmid were analyzed using a 1-way
ANOVA followed by a Dunnett’s Multiple Comparison post test. Asterisks, “*”, “**” or
“***”, denote significance compared to the corresponding vehicle control at p<0.05,
p<0.01 or p<0.001, respectively. Comparisons between reporter plasmids were analyzed
using a 2-way ANOVA Bonferroni post test. Daggers, “†††”, denote significant
differences between reporter plasmids for each treatment at p<0.001. > denotes
synergistic activation by LPS and TCDD cotreatment compared to the activation of either
treatment alone. Results are representative of at least three experiments.
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Involvement of Oct and AP1.ETS motifs and the invariant sequence in human hs1,2
enhancer activity
Like the AP1.ETS site the transcription factor, octamer (Oct-ATGCAAAT), is
located 5’ of the invariant sequence (IS). Oct contributes to mouse hs1,2 enhancer
activity and is conserved between mouse and human (Mills et al., 1997). In B cells Oct
in collaboration with G-rich, κB-like motifs and BSAP repress transcription of the murine
hs1,2 enhancer (Singh and Birshtein, 1996). Even though little is known of TCDDinduced effects on Oct, its active role in enhancer activity makes it a site of interest.
Furthermore, the binding motif is frequently present in AhR-sensitive genes (Kel et al.,
2004), which means that it could have a vital role in AhR signaling and TCDD-induced
modulation. When Oct was mutated (α1AOctmut) from the α1A plasmid and transiently
transfected into CH12.LX cells, transcriptional activity increased for unstimulated and
LPS-stimulated treatments both with and without TCDD (Fig. 14A).

Interestingly,

mutation of Oct generated a significant increase in unstimulated TCDD-induced foldchange activation compared to α1A (Fig. 14B). When the Oct was mutated from the
α1AISdel (α1AOctmutISdel) there was still more luciferase activity than the α1A wildtype
and even the α1AOctmut (Fig. 14A). Also, stimulated TCDD-induced fold changes of the
α1AOctmutISdel were not as high as the α1A (Fig. 14B).
To assess relative differences in transcriptional activity VH, α1A, α1AAP1.ETSmut,
α1AOctmutISdel, and α1AISdel were transiently transfected into CH12.LX cells.
Transfecting the α1AAP1.ETSmut and α1AISdel together will indicate the degree of
transcriptional suppression between one another in comparison to V H and α1A activity.
The α1AAP1.ETSmut showed luciferase activity only slightly higher than V H levels, but
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noticeably lower than α1AISdel, which suggests the AP1.ETS site is responsible for more
enhancer activity than the IS (Fig. 15).

Also, evaluating the α1AOctmutISdel and

α1AISdel together in this experimental design will address what impact mutating the Oct
site has in combination with the IS deletion. Deletion of the IS by itself lowered
transcriptional activity of the hs1,2 enhancer, as previously seen, but with the Oct
additionally mutated there seems to be a dramatic increase in activity (Fig. 15). It is
possible that deletion of the IS and mutation of the Oct site together acquit the enhancer
of any inhibition and allow for full activity of the AP1.ETS site.
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Figure 14. Mutations involving Oct increase transcriptional activity of the hs1,2
enhancer.
CH12.LX cells were transiently transfected with α 1A, α1AOctmut,
α1AISdelOctmut or α1AISdel reporter plasmids. Transfected cells were either cultured in
the absence of any additional treatment (naïve, NA) or treated for 24 h with 0.01%
DMSO vehicle (0 nM TCDD) or TCDD (0.01-10.0 nM) in the absence or presence of
LPS (0.1 µg/ml) stimulation. C represents the LPS alone control. A. Luciferase enzyme
activity (mean ± SEM, n=3) is represented on the y-axis as relative light units (RLUs)
normalized to transfection efficiency. B. TCDD-induced activation is represented on the
y-axis as fold change relative to the DMSO vehicle. Results (mean ± SEM) were
generated from separate experiments (n=3 for each treatment group within each
experiment). Comparisons between treatment groups of the same plasmid were analyzed
using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post test.
Asterisks, “*”, “**” or “***”, denote significance compared to the corresponding vehicle
control at p<0.05, p<0.01 or p<0.001, respectively. Comparisons between reporter
plasmids were analyzed using a 2-way ANOVA Bonferroni post test. Daggers, “††” or
“†††”, denote significant differences between reporter plasmids for each treatment at
p<0.01 and p<0.001, respectively. Vertical line also represents significance at p<0.001.
> denotes synergistic activation by LPS and TCDD cotreatment compared to the
activation of either treatment alone. Results are representative of at least three
experiments.
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Figure 15. Mutating the AP1.ETS site decreases hs1,2 transcriptional activity more
than deletion of the IS. CH12.LX cells were transiently transfected with VH, α1A,
α1AISdel, α1AISdelOctmut or α1AAP1.ETSmut. Transfected cells were either cultured in
the absence of any additional treatment (naïve, NA) or treated for 24 h with 0.01%
DMSO vehicle (0 nM TCDD) or TCDD (10.0 nM) in the absence or presence of LPS
(0.1 µg/ml) stimulation. C represents the LPS alone control. A. Luciferase enzyme
activity (mean ± SEM, n=3) is represented on the y-axis as relative light units (RLUs)
normalized to transfection efficiency. B. TCDD-induced activation is represented on the
y-axis as fold change relative to the DMSO vehicle. Results (mean ± SEM) were
generated from separate experiments (n=3 for each treatment group within each
experiment). Comparisons between treatment groups of the same plasmid were analyzed
using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post test.
Asterisks, “*”, “**” or “***”, denote significance compared to the corresponding vehicle
control at p<0.05, p<0.01 or p<0.001, respectively. Results are representative of three
experiments.
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IV. DISCUSSION
The role of Pax5 in mediating TCDD-induced activity of the human hs1,2 enhancer
Pax5 (BSAP) is a transcription factor that plays a vital role in B-cell development
and differentiation. It is present in pro-B, pre-B and mature B cells yet absent in plasma
cells. Pax5 represses IgH expression by suppressing the 3’IgH RR and its natural loss in
the plasma cell stage resultantly contributes to the activation of the murine 3’IgH RR and
Ig expression (Singh and Birshtein, 1993; Neurath, 1994). Opposite of the murine hs1,2
enhancer, hs4 enhancer activity is upregulated by BSAP binding, which occurs in early B
cell lineage (Mills et al., 1997). The one BSAP site found in the mouse hs4 enhancer is
not found in the human hs4 enhancer indicating its presence is unnecessary for human
hs4 activation (Mills et al., 1997). A previous study indicated inhibition of mouse hs1,2
enhancer activity through collaborative binding involving BSAP sites, an octamer
sequence, a G-rich sequence and possibly an NF-κB binding site (Michaelson et al.,
1996; Singh and Birshtein, 1996).

Altered binding of these same sites allows for

activation of the mouse hs1,2 enhancer following the loss of Pax5 that occurs following
B-cell activation (Singh and Birshtein, 1996). It is possible that absence of a Pax5
binding site in the human hs1,2 enhancer may partially explain TCDD-induced inhibition
of the mouse hs1,2 enhancer versus TCDD-induced activation of the human hs1,2
enhancer.
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LPS stimulation of mouse B cells decreases Pax5 mRNA and protein levels and
binding beginning at 48 hrs post-stimulation (Yoo et al., 2004). When B cells are
activated by LPS in the presence of TCDD, inhibition of the expected decrease in Pax5
levels is observed beginning at 48 hrs post-stimulation (Yoo et al., 2004). Disturbance in
the downregulation of Pax5 by TCDD is also consistent with repression of IgH, Igκ and J
chain mRNA, which provides evidence that Pax5 is a key player in TCDD-induced
suppression of the IgM response (Yoo et al., 2004, Schneider et al., 2008). It is possible
that a DRE site in the Pax5 promoter is mediating TCDD-induced effects. Like mouse,
Pax5 is similarly present in human (e.g. IM-9 B lymphoblasts). A previous study
indicated the TCDD-induced AhR recognized a Pax5 site in the promoter region of the
CD19 gene, but this was because of a DRE site contained within the Pax5 site (Masten
and Shiverick, 1995). While Pax5 is seemingly involved in TCDD/AhR signaling in
mouse, its role in human Ig production remains largely in question.
As expected, addition of the high-affinity Pax5 binding site to the human hs1,2
enhancer demonstrated a repressor role by decreasing overall transcriptional activity of
the enhancer (Fig. 7A). Also, synergism from cotreatment of LPS and TCDD was not
evident with α1A + Pax5 (Fig. 7A). TCDD-induced fold-change activation of the human
α1A, however, remained unaffected by the presence of the Pax5 binding site (Fig. 7B).
Even though inhibition of hs1,2 enhancer activity by TCDD as seen in the mouse was not
similarly demonstrated by the α1A + Pax5, Pax5 signaling is highly complex. Not only
does Pax5 interact with other transcription factors, as previously mentioned, but it can
display dual functions in B lymphocytes or undergo alternative splicing (Pinaud et al.,
2011). Pax proteins are also able to regulate responses by inducing conformational
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changes to DNA so it is possible that the murine high-affinity Pax5 site by itself (i.e.
without low-affinity Pax5) was not sufficient in generating TCDD-mediated inhibition of
the human hs1,2 enhancer (Chalepakis, 1994; Epstein et.al., 1994). Furthering the current
study by adding the low affinity Pax5 site of the murine hs1,2 enhancer to the α1A + Pax5
would help rule out this possibility. Also, transient transfections were conducted at 24
hrs and LPS decreases Pax5 activity beginning at 48 hrs (Yoo et al., 2004). Even though
TCDD-induced activation remained unaffected between α1A and α1A + Pax5 in this study,
the role of Pax5 in how TCDD differentially modulates the mouse and human hs1,2
enhancer cannot be disregarded.
Mutation of the high-affinity Pax5 site in the mouse hs1,2 reporter plasmid was
also attempted throughout the duration of this project, but efforts remained unsuccessful.
Several different approaches were taken to improve problems with low transformation
efficiency and sequencing failure, such as increasing amounts of parental template,
dNTP, mutant primers and/or adjusting PCR conditions. The size of the reporter plasmid
(~9 kb) in conjunction with repetitive DNA regions may be generating problematic
secondary structures that hinder mutant plasmid extension in the thermal cycling step.
Sequencing of the mouse hs1,2 reporter plasmid has ensured its quality so future attempts
would be worthwhile.

Activation of the human polymorphic hs1,2 enhancer by TCDD is AhR-dependent
The mechanism of TCDD-induced toxicity has been most well-defined through
the aryl hydrocarbon receptor signaling pathway. Historically, this pathway has been
mapped out with the TCDD/AhR complex binding DRE sites in the promoter or enhancer
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regions of genes for drug-metabolizing enzymes. By using the AhR antagonist, CH223191, it was confirmed that TCDD-induced activation of the human polymorphic hs1,2
enhancer requires the AhR. It still remains unclear whether the AhR is directly or
indirectly involved in the pathway, since the receptor complex can directly bind DRE
sites or alter DNA binding or expression of other transcription factors such as AP-1, NFκB and SP1 (Kobayashi, 1996; Tian et al., 1999; Suh, 2002).
Experimental outcomes show the magnitude of TCDD-induced fold change
activation did not change between α1A, α1B and α1C. However, the amount of overall
transcriptional activity is dependent upon the number of IS present.

The reporter

plasmids all experienced synergistic activation from cotreatment of LPS and 10 nM
TCDD as well. Either one invariant sequence is enough to drive activation of the
enhancer by TCDD and/or one or more binding sites outside of the polymorphic is
involved.
As previously noted, α1C does not have a conserved DRE or AP-1 site in the third
IS so a mutant plasmid (α1CClinical) has been generated restoring both sites back to their
respective, consensus sequences. Transient transfection and analysis of this plasmid will
further establish whether or not there is any correlation between number of IS and degree
of TCDD-induced fold change. Additionally, the third IS has been deleted from the α1C
(IS3delα1C). Evaluation of this mutant plasmid may show a decrease in basal and LPS
levels as seen by the α1AISdel and α1BIS1del and further credit the IS for possessing a
significant amount of transcriptional activity.

As such, individual mutation of

transcription factor binding motifs of the human hs1,2 enhancer will better pinpoint
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which sites are involved in TCDD-induced modulation of the enhancer and its overall
activity.

Involvement of the transcription factors of the invariant sequence in human hs1,2
activity
The invariant sequence contains a DRE, AP-1, NF1 and NF-κB site flanked by
SP1 sites on both ends of the polymorphism (Chen and Birshtein, 1997; Denizot et al.,
2001; Giambra et al., 2005; Fernando et al., 2012). Activator protein 1 (AP-1) is a
heterodimer protein composed of c-Fos and c-Jun while nuclear factor kappa B (NF-κB)
is also a heterodimer protein composed of different members of Rel family transcription
factors. Both have been associated with altered binding or regulation by the AhR or
TCDD (Tian et al., 1999; Suh et al., 2002). In LPS-activated CH12.LX cells TCDD
suppressed AP-1 binding to AP-1 recognition sites within the B lymphocyte-induced
maturation protein-1 (Blimp-1) promoter, which was in concordance with suppression of
Blimp-1 by TCDD (Schneider et al., 2009). Blimp-1 is a critical regulator of B cell
differentiation and also acts as a transcriptional repressor to Pax5.

Following this

suppression by AP-1, Blimp-1 mRNA and DNA-binding activity within the Pax5
promoter dysregulated Pax5 (Schneider et al., 2009). In a different study, TCDD-treated
guinea pigs showed changes in protein phosphorylation that were accompanied by
increased AP-1 DNA-binding activity in liver tissue (Ashida et al., 2000). Outcomes
from these separate studies indicate that TCDD may downregulate or upregulate AP-1
activities.
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NF-κB has been identified as a key regulator of the murine hs1,2 enhancer and
physical interactions between the AhR and NF-κB have been demonstrated (Tian et al.,
2002; Michaelson et al., 1996).

Mutation of the NF-κB site from a murine hs1,2

enhancer reporter construct increased or decreased enhancer activity in a cell-stage
dependent manner thus suggesting an important role for κB binding proteins in
modulating the hs1,2 enhancer (Michaelson et al., 1996). Also, EMSA-Western Analysis
showed TCDD-induced binding of NF-κB/Rel proteins to a κB site with an overlapping
DRE in the hs4 enhancer (Sulentic et al., 2000). The potential for a check-and-balance
relationship between the NF-κB and AhR pathway has further been demonstrated, which
may occur through negative regulation when one receptor binds within the other
receptor’s promoter (Tian et al., 2002)
In the current study mutation of the AP-1 site and NF-κB site increased basal and
LPS levels of the α1A human hs1,2 enhancer (Fig. 11A and 12A). Like the α1A, a TCDDconcentration response was also observed with both the α1AAP1mut and α1ANFκBmut
(Fig. 11A and 12A). An increase in overall transcriptional activity caused by mutation of
the AP-1 or NF-κB could mean that these sites naturally have repressor roles.
Alternatively, other sites present in the enhancer (i.e. AP1.ETS, Oct, SP1, DRE, NF1)
may compensate for any loss in transcription from the AP-1 or NF-κB site and overly
adjust activity as a result. Since the previously mentioned studies imply that AP-1 and
NF-κB can be affected by the AhR and/or TCDD, it is reasonable to think that either one
of these binding motifs are responsible for TCDD’s ability to activate the human hs1,2
enhancer. Outcomes from this study, however, suggest otherwise. TCDD-induced foldchanges of α1AAP1mut and α1ANFκBmut had slightly lower stimulated fold-changes

57

compared to the α1A. This may suggest that the AP-1 and NF-κB binding-motifs each are
one of several binding-motifs that coordinate TCDD-induced hs1,2 enhancer activation in
stimulated CH12.LX cells in addition to repressing basal and stimulated enhancer
activity.
Because slightly lower TCDD-induced fold changes resulted from mutation of the
AP-1 and NF-κB sites, creating a plasmid from the α1A that has both of these sites
mutated would be beneficial. A double mutant of the α1A containing a mutated DRE and
NF-κB has already been created, but still needs to be tested. One study indicated the
importance of multiple binding sites when it demonstrated that in addition to a DRE, an
NF-κB site was involved in TCDD-induced regulation of Fas and FasL promoters (Singh,
2007). As such, plasmids containing mutations of two or more transcription factor
binding sites would help tease apart the complexity of how TCDD induces the human
hs1,2 enhancer.
At this time concluding remarks cannot be made about the role the DRE may play
in modulating TCDD-induced activation of the human hs1,2 enhancer. Nevertheless, a
plasmid containing a mutated DRE site from the α1A (α1ADREmut) has been created and
initial efforts are suggesting an increase in overall transcriptional activity with no
difference in fold change. Additional DREs do not seem to increase the magnitude of
TCDD-induced fold change, but the AhR certainly mediates TCDD-induced activity as
seen from antagonist experiments (Fig. 8B). It may be that one DRE site is enough to
drive TCDD’s activation of the hs1,2 enhancer or it simply has minimal involvement.
Also, the IS DRE site may affect basal and LPS-induced transcriptional activity since
overall hs1,2 enhancer activity increases with the number of IS (Fig. 8A). Results from
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transient transfections of the α1ADREmut will determine if the drop in transcription that
resulted from deletion of the IS is related to the DRE site.
The NF1, also located within the α1A IS, has not yet been mutated. Analysis of
this binding motif is critical, because a complete and comprehensive study will have been
performed on every IS binding site. Deletion of an IS from the α1A and α1B showed a
decrease in overall transcriptional activity whereas mutation of the AP-1 and NF-κB sites
showed an increase.

Analysis of the DRE and NF1 site may better explain this

contradictory outcome. Upon individual evaluation of the NF-κB, DRE, AP-1 and NF1 it
will also be known which sites impact overall transcriptional activity the most and how.
Additional mutation studies will determine if the DRE and NF1 mediate TCDD-induced
fold change of the human hs1,2 enhancer is substantially altered. Following a thorough
assessment of each IS binding-motif, greater care can be taken as to which combination
of multiple binding sites should be mutated from the parental α1A. At this time it seems
that TCDD-induced modulation of the hs1,2 enhancer is not driven solely through one
binding site, but rather two or more.

Transcriptional role of binding-motifs located outside the invariant sequence
Located 5’ and furthest from the IS is an AP1.ETS binding site. An earlier study
identified binding of a novel DNA binding complex, nuclear factor of activated B cells
(NFAB), to an AP1.ETS site of the mouse 3’IgH RR that supported enhancer activation
following cross-linking of surface IgM (Grant et al., 1995). Also, in a study involving a
melanoma cell line, matrix metalloproteinase promoter activity was increased when an
AP1.ETS site was formed from an AP-1 site adjacent to a polymorphic ETS element
59

(Villano et al., 2006).

Despite increased promoter activity, however, the ETS

polymorphism did not alter TCDD-induced activity compared to the wildtype (Villano et
al., 2006). Outcomes from these studies certainly highlight potential for the human hs1,2
AP1.ETS site to possess an active role in the enhancer’s activity. Out of all of the
individual binding sites mutated and analyzed thus far, mutation of the AP1.ETS site
(α1AAP1.ETSmut) was the only one that showed a decrease in transcriptional activity of
the hs1,2 enhancer when transiently transfected into CH12.LX cells (Fig. 13A). A drop
in luciferase activity in both unstimulated and LPS-stimulated cells underscores the
importance this site has in mediating human hs1,2 enhancer activity. Evaluation of the
α1AAP1.ETSmut still showed that TCDD-induced fold change did not differ from the α1A,
but α1A did experience more synergism (Fig. 13A and 13B).
Also located 5’ and outside the IS is an octamer (Oct) site, which has been less
studied in regards to AhR or TCDD-induced modulation.

Nevertheless, NF-κB in

combination with Oct transcription factors seem to contribute to the activity of the mouse
hs1,2 enhancer in plasma cells while Pax5 is concurrently downregulated (Michaelson,
1996). Also, Oct binding sites are frequently found in AhR-sensitive genes suggesting a
possible role in the AhR signaling network (Kel et al., 2004). Mutation of the Oct site
(α1AOctmut) resulted in an increase in overall transcriptional activity of the human hs1,2
enhancer when transiently transfected into CH12.LX cells suggesting an innate repressor
role of the enhancer’s activity (Fig. 14A).

Interestingly, the α1AOctmut showed a

significantly higher degree of TCDD-induced activation when compared to the α1A, but
this was only seen in unstimulated cells. Under this circumstance, Oct may naturally
hinder hs1,2 activation by TCDD when LPS is not involved.
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When transiently

transfected cells are LPS-stimulated, however, there appears to be no differences in
TCDD-induced fold changes between the α1AOctmut and α1A (Fig. 14B). LPS signaling
must somehow disturb the mechanism that was involved in the increased fold-change of
α1AOctmut activation by TCDD experienced in unstimulated cells.
Interestingly, mutating the Oct site in conjunction with deletion of the IS from the
α1A (α1AOctmutISdel) experienced more overall transcriptional activity than α1AOctmut
(Fig. 14A). The α1AOctmutISdel did not always experience consistent TCDD-induced
activation and stimulated fold changes were on average lower than α1A (Fig. 14A, 14B
and 15). One of the binding sites deleted or mutated must certainly be responsible for
TCDD-induced activation of the hs1,2 enhancer, since the only remaining binding site is
the AP1.ETS. Otherwise some sort of inconsistent compensating mechanism may be
taking place. The IS deletion could have allowed for the flanking SP1 sites of the IS to
come together to create one functional SP1 site that together with the remaining AP1.ETS
site may have generated a highly transcriptionally active reporter plasmid.
In regards to SP1, one study indicated a synergistic effect between AhR/ARNT
and SP1, which increased the drug-inducible expression of CYP1A1 in a Drosophila cell
line (Kobayashi, 1996). Another study credited an SP1-based transcription mechanism
for mediating TCDD-induced protein and mRNA expression of mucin-5AC in human
bronchial epithelial cells and an immortalized cell line that was independent of the AhR
(Lee et al., 2010). It is possible that either of the two SP1 transcription factor binding
sites play an important role in modulating the TCDD-induced activation of the human
hs1,2 enhancer. As such, both the 5’ (α1ASP1.1mut) and 3’ (α1ASP1.2mut) SP1 sites have
been mutated from the α1A. Upon evaluation, these mutagenic plasmids will provide a
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more in-depth analysis on how these sites affect human hs1,2 transcriptional activity or
TCDD-induced modulation.
Conclusion
Ultimately, it is difficult to pinpoint the transcription factor binding sites
responsible for TCDD-induced modulation of the human hs1,2 enhancer. Differences in
the DNA sequence between the mouse and human hs1,2 enhancer and how they are
oppositely modulated by TCDD certainly emphasizes the potential difficulty in
translating mouse data to human-assessment. While addition of the mouse Pax5 site to
the α1A decreased the enhancer’s transcriptional activity, TCDD was still able to activate.
The presence of two Pax5 binding sites in the mouse hs1,2 enhancer versus none in the
human may still explain why TCDD inhibits mouse activity yet activates human. The
high-affinity Pax5 was added to the α1A in a way that best mirrored the mouse hs1,2
enhancer, but changes in the double helix or secondary structures of the mutant plasmid
may have somehow masked or overridden TCDD-induced inhibition. Otherwise, the
involvement Pax5 has in mouse hs1,2 enhancer activity and TCDD responsiveness could
simply be unrelated or unnecessary in the human hs1,2 enhancer.
Based on the other binding sites that have been evaluated in this study (AP-1, NFκB, Oct, AP1.ETS), none seem to be the sole driving force behind TCDD’s ability to
activate the human hs1,2 enhancer. Mutation of the AP-1 and NF-κB site showed slight
decreases in TCDD-induced fold-change activation, however, outcomes were not
statistically significant.

It seems very likely that several transcription factors are

simultaneously involved in mediating the effect of TCDD. Even though deletion of the
IS shows no change in TCDD-induced activation of the human hs1,2 enhancer, EMSA
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analyses indicate that TCDD induces binding within the IS in LPS-stimulated CH12.LX
cells (data not shown). Future efforts will focus on isolating and identifying proteins
bound to the IS by mass spectrometry.
Individual site mutations of AP-1, NF-κB and Oct increased human hs1,2
transcriptional activity suggesting repressor roles while mutation of AP1.ETS lowered
overall enhancer activity (Fig. 16). The AP1.ETS site seems to control much human
hs1,2 enhancer activity, since it is the only site thus far that has shown a drop in
transcription when mutated. Deletion of the IS lowered transcriptional activity as well,
but again it is difficult to discern which IS binding site(s) is/are of cause (Fig. 16).
Furthermore, deleting rather than mutating the IS could be creating an inauthentic
outcome due to changes in the secondary structure. It would be worthwhile to generate
one plasmid where all the IS binding sites have undergone mutation in order to reinforce
results. So far it seems the AP-1 and NF-κB sites may be involved in TCDD-induced
fold-change activation of the enhancer underscoring the likelihood of a complex network
of interacting transcription factors. Like AP-1 and NF-κB, the Oct site also showed a
drop in fold change, but only in LPS-stimulated cells thus exemplifying signaling
differences between unstimulated and stimulated hs1,2 enhancer modulation.
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AP-1/Ets

Oct

TGACTCATTCT

ATGCAAAT

*

24 bp
73 bp

Sp1

DRE

CCCGCCCCCT

GCGTG
6 bp

AP-1

NF1

NF-κB

7 bp

Sp1

GGGACACCCGCCCCCT

TGGCTCAGGCCTCCA
6 bp

?

?

?

*
55 bp sequence

* ISdelOctmut =

Figure 16. Overall transcriptional activity outcomes of deletion/mutagenic plasmids
compared to the human α1A. Up or down arrow means greater or less overall
transcriptional activity than α1A. Question mark: results to be determined.
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A number of limitations persist in this study in addition to those already reported.
First, fold change calculations do not provide a tell-all tale to TCDD-induced regulation.
Overall increases or decreases in TCDD-induced transcription translate into real effects,
which is a different perspective than simply magnitude of fold change. Second, there may
be transcription factors or binding sites present in the hs1,2 enhancer that have not been
identified. Enhancer activity and TCDD-induced regulation could possibly be driven
through other unrecognized means. Finally, it is uncertain how accurately this research
reflects the endogenous human IgH. Not only are outcomes not in the context of
chromatin, but transcriptional activity is based on reporter plasmids containing a human
gene transfected into murine B cells.

While the CH12.LX cells have been used

extensively and contain a functional AhR pathway, current efforts are being made to
characterize and develop a human B cell line that can be ligand-activated. In spite of
these limitations, this study lays the groundwork for uncovering hs1,2 regulation.
Overall, the hs1,2 enhancer has an important role in 3’IgH RR functioning, so
understanding how TCDD or other AhR-ligands modulate it will provide greater insight
into how chemically-induced immunotoxic effects are mediated. Also, its involvement in
the severity and prevalence of a number of autoimmune diseases makes it an area of
interest. Teasing apart the mechanism at hand could ultimately lead to the manipulation
of the many disease states associated with the 3’IgH RR and human hs1,2 enhancer.
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